United Therapeutics Corp
$497.27
Market Cap
$21.33B
Shares Outstanding
42.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 17, 1999
Round Lot
40
Locale
US
Day Open
$501.49
Day High
$503.32
Day Low
$492.59
Volume
1.45M
VWAP
$497.44
Prev Close
$498.48
Transactions
--
Acc. Volume
--
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
United Therapeutics Corp (UTHR) closed the 2026-09-17 session at $497.27, down 0.24% versus the previous close (-1.21). The stock opened at $501.49 and traded between $492.59 and $503.32 during that session. Session trading volume was 1.5M shares. The volume-weighted average price (VWAP) is $497.44.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
United Therapeutics Corp has a market capitalization of $21.33 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. UTHR is listed on the XNAS exchange. The company employs approximately 1,400 people. United Therapeutics Corp is headquartered in SILVER SPRING, MD. The recorded listing date is 1999-06-17.
On this page you can find market UTHR stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.